Last €0.31 EUR
Change Today -0.009 / -2.84%
Volume 0.0
As of 2:08 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

ekf diagnostics holdings plc (LYF) Snapshot

Open
€0.31
Previous Close
€0.32
Day High
€0.31
Day Low
€0.31
52 Week High
03/6/14 - €0.42
52 Week Low
01/20/15 - €0.24
Market Cap
130.0M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
422.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EKF DIAGNOSTICS HOLDINGS PLC (LYF)

Related News

No related news articles were found.

ekf diagnostics holdings plc (LYF) Related Businessweek News

No Related Businessweek News Found

ekf diagnostics holdings plc (LYF) Details

EKF Diagnostics Holdings plc is engaged in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the United Kingdom, the United States, Germany, Poland, Russia, Ireland, and Asia. The company offers near patient analyzers for the measurement of glucose, lactate, hemoglobin, hematocrit, and HbA1c. Its products include glycated hemoglobin analyzers, such as Quo-Test, Quo-Lab, and Biosen HbA1c analyzers for monitoring diabetes; hemoglobin analyzers consisting of Hemo Control and Hemo Vet, which are point of care devices to provide results for hemoglobin and hematocrit, as well as STAT-Site M Hgb, a hand-held device for blood screening programs; and glucose analyzers comprising Biosen C-Line and S-Line glucose and lactate analyzers, and Lactate Scout+, a hand-held lactate analyzer. The company also provides rapid testing services, including pregnancy tests, such as True20, QuPID, and QuStick for urine only or urine and serum pregnancy testing; and infectious diseases tests, such as H. Pylori, RELY Mono, RELY and Strep A, and QuStick for the detection of pathonogenic micro-organisms, such as bacteria, parasites, viruses, and fungi. In addition, it offers clinical chemistry reagents; and biomarker diagnostic kits used by researchers and clinicians, as well as molecular diagnostic test kits, which are focused on applications within oncological research. The company sells its products to GP surgeries, pharmacies, blood banks, sports clinics, hospitals, and laboratories through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

330 Employees
Last Reported Date: 02/26/14
Founded in 1990

ekf diagnostics holdings plc (LYF) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 297.0K GBP
Executive Chairman
Total Annual Compensation: 45.0K GBP
Finance Director, Secretary and Executive Dir...
Total Annual Compensation: 19.0K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 214.0K GBP
Compensation as of Fiscal Year 2013.

ekf diagnostics holdings plc (LYF) Key Developments

EKF Diagnostics Holdings plc Announces a Major 18 Month Collaboration in the US, for its PrecisionPath Technology

EKF Diagnostics Holdings plc announced a major 18 month collaboration in the US, using the company's PrecisionPath™ technology to provide genetic profiles of cancer tumours, which, if successful, will lead to greatly improved treatment decisions for colon cancer patients. EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, announces a major 18 month collaboration in the US, using the Company's PrecisionPath™ technology to provide genetic profiles of cancer tumours, which, if successful, will lead to greatly improved treatment decisions for colon cancer patients. The collaboration brings together EKF's subsidiary Selah Genomics; Greenville Health Systems, one of the leading cancer institutes in the US; DecisionQ Corporation; and Becton Dickinson and Company, with the aim of creating a new way for community doctors to decide on the most effective treatments for colon cancer using the latest next generation sequencing technology as well as artificial intelligence-based decision support algorithms. Over the 18 month period, EKF's PrecisionPath™ will be used to determine the genetic profiles of tumour samples provided by the Institute for Translational Oncology Research, which is part of Greenville Health Systems' Cancer Institute. At the same time DecisionQ will employ its advanced machine-learning platform to integrate the genetic profile data with existing clinical annotations and the known outcomes of the patient samples to validate the treatment indicated by the genetic profiling. If the results successfully correlate, then this will help validate EKF's PrecisionPath™ product in being able to improve clinical decisions related to the treatment of colon cancer patients.

EKF Diagnostics Holdings plc Provides Financial Guidance for the Year Ended December 31, 2014; Announces Revenue Results for the Second Half of 2014

EKF Diagnostics Holdings plc provides financial guidance for the year ended December 31, 2014. The company now expects results for the year ended 31 December 2014 to be at the higher end of previous management guidance, with unaudited revenues of around £40.1 million, a 26% improvement on the previous year revenue of £31.8 million despite revenues being impacted negatively by exchange rate differences of £2.6 million. Unaudited adjusted EBITDA is expected to be up 31% to £6.3 million compared to £4.8 million reported in the same period last year. For the second half year, the company has reported revenue of £23.3 million, up 38% against the same period in 2013, and a 39% improvement on the previous half 2014. Underlying organic revenues accounted for £33.6 million of total revenues which represented 6% organic growth year-on-year.

EKF Diagnostics Holdings plc Provides Unaudited Earnings Guidance for the Full Year Ending December 31, 2014

EKF Diagnostics Holdings plc provided unaudited earnings guidance for the full year ending December 31, 2014. For the period, the company's financial results are expected to be below consensus expectations. The company expects that unaudited revenues will show at least an increase of 24% on the previous year to £39.5 million. Unaudited adjusted EBITDA is expected to be at least 29% up on the previous year at £6.2 million. Excluding the effect of exchange rates, revenue would have been expected to be up at least 30% year on year and adjusted EBITDA would have been expected to be up at least 37%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LYF:GR €0.31 EUR -0.009

LYF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LYF.
View Industry Companies
 

Industry Analysis

LYF

Industry Average

Valuation LYF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book 0.8x
Price/Cash Flow 7,067.3x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EKF DIAGNOSTICS HOLDINGS PLC, please visit www.ekfdiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.